Technical Strategy for Pancreatic Body Cancers: A Raison d'etre of Distal Pancreatectomy with Portal Resection.

Distal pancreatectomy Pancreatic body cancer Pancreaticoduodenectomy Portal vein resection Surgical indication

Journal

Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840

Informations de publication

Date de publication:
11 Nov 2023
Historique:
received: 19 07 2023
accepted: 22 10 2023
medline: 12 11 2023
pubmed: 12 11 2023
entrez: 11 11 2023
Statut: aheadofprint

Résumé

Advancements in multiagent chemotherapy have expanded the surgical indications for pancreatic cancer. Although pancreaticoduodenectomy (PD) with portal vein resection (PVR) has become widely adopted, distal pancreatectomy (DP) with PVR remains rarely performed because of its technical complexity. This study was designed to assess the feasibility of DP-PVR compared with PD-PVR for pancreatic body cancers, with a focus on PV complications and providing optimal reconstruction techniques when DP-PVR is necessary. A retrospective review was conducted on consecutive pancreatic body cancer patients who underwent pancreatectomy with PVR between 2005 and 2020. An algorithm based on the anatomical relationship between the arteries and PV was used for optimal surgical selection. Among 119 patients, 32 underwent DP-PVR and 87 underwent PD-PVR. Various reconstruction techniques were employed in DP-PVR cases, including patch reconstruction, graft interposition, and wedge resection. The majority of PD-PVR cases involved end-to-end anastomosis. The length of PVR was shorter in DP-PVR (25 vs. 40 mm; p < 0.001). Although Clavien-Dindo ≥3a was higher in DP-PVR (p = 0.002), inpatient mortality and R0 status were similar. Complete PV occlusion occurred more frequently in DP-PVR than in PD-PVR (21.9% vs. 1.1%; p < 0.001). A cutoff value of 30 mm for PVR length was determined to be predictive of nonrecurrence-related PV occlusion after DP-PVR. The two groups did not differ significantly in recurrence or overall survival. DP-PVR had higher occlusion and postoperative complication rates than PD-PVR. These findings support the proposed algorithm and emphasize the importance of meticulous surgical manipulation when DP-PVR is deemed necessary.

Sections du résumé

BACKGROUND BACKGROUND
Advancements in multiagent chemotherapy have expanded the surgical indications for pancreatic cancer. Although pancreaticoduodenectomy (PD) with portal vein resection (PVR) has become widely adopted, distal pancreatectomy (DP) with PVR remains rarely performed because of its technical complexity. This study was designed to assess the feasibility of DP-PVR compared with PD-PVR for pancreatic body cancers, with a focus on PV complications and providing optimal reconstruction techniques when DP-PVR is necessary.
METHODS METHODS
A retrospective review was conducted on consecutive pancreatic body cancer patients who underwent pancreatectomy with PVR between 2005 and 2020. An algorithm based on the anatomical relationship between the arteries and PV was used for optimal surgical selection.
RESULTS RESULTS
Among 119 patients, 32 underwent DP-PVR and 87 underwent PD-PVR. Various reconstruction techniques were employed in DP-PVR cases, including patch reconstruction, graft interposition, and wedge resection. The majority of PD-PVR cases involved end-to-end anastomosis. The length of PVR was shorter in DP-PVR (25 vs. 40 mm; p < 0.001). Although Clavien-Dindo ≥3a was higher in DP-PVR (p = 0.002), inpatient mortality and R0 status were similar. Complete PV occlusion occurred more frequently in DP-PVR than in PD-PVR (21.9% vs. 1.1%; p < 0.001). A cutoff value of 30 mm for PVR length was determined to be predictive of nonrecurrence-related PV occlusion after DP-PVR. The two groups did not differ significantly in recurrence or overall survival.
CONCLUSIONS CONCLUSIONS
DP-PVR had higher occlusion and postoperative complication rates than PD-PVR. These findings support the proposed algorithm and emphasize the importance of meticulous surgical manipulation when DP-PVR is deemed necessary.

Identifiants

pubmed: 37952022
doi: 10.1245/s10434-023-14554-5
pii: 10.1245/s10434-023-14554-5
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2023. Society of Surgical Oncology.

Références

Machairas N, Raptis DA, Velazquez PS, et al. The impact of neoadjuvant treatment on survival in patients undergoing pancreatoduodenectomy with concomitant portomesenteric venous resection: an International Multicenter Analysis. Ann Surg. 2021;274(5):721–8. https://doi.org/10.1097/SLA.0000000000005132 .
doi: 10.1097/SLA.0000000000005132 pubmed: 34353988
Nagakawa Y, Jang JY, Kawai M, et al. Surgical outcomes of pancreatectomy with resection of the portal vein and/or superior mesenteric vein and jejunal vein for pancreatic head cancer: A multicenter study. Ann Surg. 2021. https://doi.org/10.1097/SLA.0000000000005330 .
doi: 10.1097/SLA.0000000000005330 pubmed: 34913900
Oba A, Ito H, Ono Y, et al. Regional pancreatoduodenectomy versus standard pancreatoduodenectomy with portal vein resection for pancreatic ductal adenocarcinoma with portal vein invasion. BJS Open. 2020;4(3):438–48. https://doi.org/10.1002/bjs5.50268 .
doi: 10.1002/bjs5.50268 pubmed: 32191395 pmcid: 7260410
Del Chiaro M, Segersvard R, Rangelova E, et al. Cattell-Braasch maneuver combined with artery-first approach for superior mesenteric-portal vein resection during pancreatectomy. J Gastrointest Surg. 2015;19(12):2264–8. https://doi.org/10.1007/s11605-015-2958-1 .
doi: 10.1007/s11605-015-2958-1 pubmed: 26423804
Raptis DA, Sanchez-Velazquez P, Machairas N, et al. Defining benchmark outcomes for pancreatoduodenectomy with portomesenteric venous resection. Ann Surg. 2020;272(5):731–7. https://doi.org/10.1097/SLA.0000000000004267 .
doi: 10.1097/SLA.0000000000004267 pubmed: 32889866
Oba A, Kato T, Inoue Y, et al. Extent of venous resection during pancreatectomy-finding the balance of technical possibility and feasibility. J Gastrointest Oncol. 2021;12(5):2495–502. https://doi.org/10.21037/jgo-21-129 .
doi: 10.21037/jgo-21-129 pubmed: 34790410 pmcid: 8576227
Strasberg SM, Sanchez LA, Hawkins WG, Fields RC, Linehan DC. Resection of tumors of the neck of the pancreas with venous invasion: the “Whipple at the Splenic Artery (WATSA)” procedure. J Gastrointest Surg. 2012;16(5):1048–54. https://doi.org/10.1007/s11605-012-1841-6 .
doi: 10.1007/s11605-012-1841-6 pubmed: 22399270
Hirono S, Kawai M, Tani M, et al. Indication for the use of an interposed graft during portal vein and/or superior mesenteric vein reconstruction in pancreatic resection based on perioperative outcomes. Langenbecks Arch Surg. 2014;399(4):461–71. https://doi.org/10.1007/s00423-014-1182-x .
doi: 10.1007/s00423-014-1182-x pubmed: 24663295
Ohgi K, Sugiura T, Yamamoto Y, et al. Benign portal vein stenosis after pancreaticoduodenectomy. World J Surg. 2019;43(10):2623–30. https://doi.org/10.1007/s00268-019-05070-3 .
doi: 10.1007/s00268-019-05070-3 pubmed: 31243526
Fujii T, Nakao A, Yamada S, et al. Vein resections >3 cm during pancreatectomy are associated with poor 1-year patency rates. Surgery. 2015;157(4):708–15. https://doi.org/10.1016/j.surg.2014.12.002 .
doi: 10.1016/j.surg.2014.12.002 pubmed: 25704426
Xu D, Wu P, Zhang K, et al. The short-term outcomes of distal pancreatectomy with portal vein/superior mesenteric vein resection. Langenbeck’s Arch Surg. 2022;407(5):2161–8. https://doi.org/10.1007/s00423-021-02382-8 .
doi: 10.1007/s00423-021-02382-8
Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161(3):584–91. https://doi.org/10.1016/j.surg.2016.11.014 .
doi: 10.1016/j.surg.2016.11.014 pubmed: 28040257
Watanabe G, Ito H, Sato T, et al. Left kidney mobilization technique during radical antegrade modular pancreatosplenectomy (RAMPS). Langenbecks Arch Surg. 2019;404(2):247–52. https://doi.org/10.1007/s00423-019-01767-0 .
doi: 10.1007/s00423-019-01767-0 pubmed: 30810806
Sato T, Saiura A, Inoue Y, Takahashi Y, Arita J, Takemura N. Distal pancreatectomy with en bloc resection of the celiac axis with preservation or reconstruction of the left gastric artery in patients with pancreatic body cancer. World J Surg. 2016;40(9):2245–53. https://doi.org/10.1007/s00268-016-3550-x .
doi: 10.1007/s00268-016-3550-x pubmed: 27198999
Sato T, Inoue Y, Takahashi Y, et al. Distal pancreatectomy with celiac axis resection combined with reconstruction of the left gastric artery. J Gastrointest Surg. 2017;21(5):910–7. https://doi.org/10.1007/s11605-017-3366-5 .
doi: 10.1007/s11605-017-3366-5 pubmed: 28116666
Oba A, Inoue Y, Sato T, et al. Impact of indocyanine green-fluorescence imaging on distal pancreatectomy with celiac axis resection combined with reconstruction of the left gastric artery. HPB (Oxford). 2019;21(5):619–25. https://doi.org/10.1016/j.hpb.2018.09.023 .
doi: 10.1016/j.hpb.2018.09.023 pubmed: 30401519
Inoue Y, Saiura A, Sato T, et al. Details and outcomes of distal pancreatectomy with celiac axis resection preserving the left gastric arterial flow. Ann Surg Oncol. 2021;28(13):8283–94. https://doi.org/10.1245/s10434-021-10243-3 .
doi: 10.1245/s10434-021-10243-3 pubmed: 34143337
Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155(6):977–88. https://doi.org/10.1016/j.surg.2014.02.001 .
doi: 10.1016/j.surg.2014.02.001 pubmed: 24856119
Isaji S. [Revised 7th edition of the General Rules for the Study of Pancreatic Cancer by Japan Pancreas Society: Revised concepts and updated points. Nihon Shokakibyo Gakkai Zasshi. 2017;114(4):617–26. https://doi.org/10.11405/nisshoshi.114.617 .
doi: 10.11405/nisshoshi.114.617 pubmed: 28381778
Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, Version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(4):439–57. https://doi.org/10.6004/jnccn.2021.0017 .
doi: 10.6004/jnccn.2021.0017 pubmed: 33845462
Schwartz LH, Litiere S, de Vries E, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–7. https://doi.org/10.1016/j.ejca.2016.03.081 .
doi: 10.1016/j.ejca.2016.03.081 pubmed: 27189322 pmcid: 5737828
Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96. https://doi.org/10.1097/SLA.0b013e3181b13ca2 .
doi: 10.1097/SLA.0b013e3181b13ca2 pubmed: 19638912
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transpl. 2013;48(3):452–8. https://doi.org/10.1038/bmt.2012.244 .
doi: 10.1038/bmt.2012.244
Bell R, Ao BT, Ironside N, Bartlett A, Windsor JA, Pandanaboyana S. Meta-analysis and cost effective analysis of portal-superior mesenteric vein resection during pancreatoduodenectomy: Impact on margin status and survival. Surg Oncol. 2017;26(1):53–62. https://doi.org/10.1016/j.suronc.2016.12.007 .
doi: 10.1016/j.suronc.2016.12.007 pubmed: 28317585
Zhou Y, Zhang Z, Liu Y, Li B, Xu D. Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg. 2012;36(4):884–91. https://doi.org/10.1007/s00268-012-1461-z .
doi: 10.1007/s00268-012-1461-z pubmed: 22350478
Miyazaki M, Shimizu H, Ohtuka M, et al. Portal vein thrombosis after reconstruction in 270 consecutive patients with portal vein resections in hepatopancreatobiliary (HPB) surgery. Am J Surg. 2017;214(1):74–9. https://doi.org/10.1016/j.amjsurg.2016.12.008 .
doi: 10.1016/j.amjsurg.2016.12.008 pubmed: 28069106
Hackert T, Klaiber U, Hinz U, et al. Portal vein resection in pancreatic cancer surgery: risk of thrombosis and radicality determine survival. Ann Surg. 2022. https://doi.org/10.1097/SLA.0000000000005444 .
doi: 10.1097/SLA.0000000000005444 pubmed: 35861061
Chan KS, Srinivasan N, Koh YX, et al. Comparison between long and short-term venous patencies after pancreatoduodenectomy or total pancreatectomy with portal/superior mesenteric vein resection stratified by reconstruction type. PLoS One. 2020;15(11):e0240737. https://doi.org/10.1371/journal.pone.0240737 .
doi: 10.1371/journal.pone.0240737 pubmed: 33151977 pmcid: 7644060
McMillan MT, Christein JD, Callery MP, et al. Comparing the burden of pancreatic fistulas after pancreatoduodenectomy and distal pancreatectomy. Surgery. 2016;159(4):1013–22. https://doi.org/10.1016/j.surg.2015.10.028 .
doi: 10.1016/j.surg.2015.10.028 pubmed: 26670325
Torgeson A, Lloyd S, Boothe D, et al. Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer. Cancer. 2017;123(19):3816–24. https://doi.org/10.1002/cncr.30780 .
doi: 10.1002/cncr.30780 pubmed: 28621885
Blair AB, Sorber R, Rozich NS, Burkhart RA. A qualitative review of neoadjuvant chemotherapy in resectable pancreatic adenocarcinoma. Pancreas. 2019;48(8):973–84. https://doi.org/10.1097/MPA.0000000000001376 .
doi: 10.1097/MPA.0000000000001376 pubmed: 31425483
Kang MJ, Jang JY, Chang YR, Jung W, Kim SW. Portal vein patency after pancreatoduodenectomy for periampullary cancer. Br J Surg. 2015;102(1):77–84. https://doi.org/10.1002/bjs.9682 .
doi: 10.1002/bjs.9682 pubmed: 25393075
Okusaka T, Furuse J. Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. J Gastroenterol. 2020;55(4):369–82. https://doi.org/10.1007/s00535-020-01666-y .
doi: 10.1007/s00535-020-01666-y pubmed: 31997007 pmcid: 7080663

Auteurs

Aya Maekawa (A)

Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

Atsushi Oba (A)

Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. atsushi.oba@jfcr.or.jp.
Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan. atsushi.oba@jfcr.or.jp.

Yosuke Inoue (Y)

Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Kojiro Omiya (K)

Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Yoshihiro Ono (Y)

Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Takafumi Sato (T)

Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Shuichi Watanabe (S)

Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

Yoshihiro Uchino (Y)

Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Department of Surgery, Kurume University School of Medicine, Fukuoka, Japan.

Kosuke Kobayashi (K)

Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Hiromichi Ito (H)

Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Yozo Sato (Y)

Department of Diagnostic Ultrasound and Interventional Radiology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Department of Diagnostic and Interventional Radiology, Aichi Cancer Center, Aichi, Japan.

Minoru Tanabe (M)

Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

Akio Saiura (A)

Department of Hepatobiliary Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan.

Yu Takahashi (Y)

Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. yu.takahashi@jfcr.or.jp.

Classifications MeSH